Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Janssen QP, et al. Among authors: bahary n. J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073. J Natl Cancer Inst. 2019. PMID: 31086963 Free PMC article.
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery MA, Allen A, O'Reilly EM. Li D, et al. Among authors: bahary n. Pancreatology. 2014 Sep-Oct;14(5):398-402. doi: 10.1016/j.pan.2014.07.003. Epub 2014 Jul 18. Pancreatology. 2014. PMID: 25278310 Free PMC article. Clinical Trial.
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, Espina V, Loughran P, Lotze MT, Zeh HJ 3rd. Boone BA, et al. Among authors: bahary n. Ann Surg Oncol. 2015 Dec;22(13):4402-10. doi: 10.1245/s10434-015-4566-4. Epub 2015 Apr 24. Ann Surg Oncol. 2015. PMID: 25905586 Free PMC article. Clinical Trial.
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Allegra CJ, et al. Among authors: bahary n. J Natl Cancer Inst. 2015 Sep 14;107(11):djv248. doi: 10.1093/jnci/djv248. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26374429 Free PMC article. Clinical Trial.
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.
Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, Zuriekat AH, Wolfgang CL, Zeh HJ 3rd, Weiss MJ. Wright GP, et al. Among authors: bahary n. J Gastrointest Surg. 2016 Nov;20(11):1830-1835. doi: 10.1007/s11605-016-3256-2. Epub 2016 Sep 7. J Gastrointest Surg. 2016. PMID: 27604886
Autophagy Inhibition in Pancreatic Adenocarcinoma.
Boone BA, Zeh HJ 3rd, Bahary N. Boone BA, et al. Among authors: bahary n. Clin Colorectal Cancer. 2018 Mar;17(1):25-31. doi: 10.1016/j.clcc.2017.10.013. Epub 2017 Oct 28. Clin Colorectal Cancer. 2018. PMID: 29223362 Review.
Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, Zeh HJ III, Tublin ME. Borhani AA, et al. Among authors: bahary n. AJR Am J Roentgenol. 2020 Feb;214(2):362-369. doi: 10.2214/AJR.19.21152. Epub 2019 Dec 4. AJR Am J Roentgenol. 2020. PMID: 31799875 Free PMC article. Clinical Trial.
149 results